Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.


Amiche A., Tanriover M. D. , Bellier L., Ugur B., Akin L.

Value in health regional issues, vol.25, pp.15-22, 2021 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25
  • Publication Date: 2021
  • Doi Number: 10.1016/j.vhri.2020.11.006
  • Title of Journal : Value in health regional issues
  • Page Numbers: pp.15-22
  • Keywords: cost, cost utility, economic analysis, incremental cost-effectiveness ratio, influenza, influenza B virus, public health impact, seasonal influenza, Turkey, vaccination, vaccine, PUBLIC-HEALTH IMPACT, SEASONAL INFLUENZA, SURVEILLANCE, PRODUCTIVITY, STATES

Abstract

Objectives: Trivalent influenza vaccines (TIVs) are widely used but protect against only 1 of the 2 co-circulating influenza B virus lineages. Quadrivalent influenza vaccines (QIVs) include a B strain from each lineage to overcome mismatches. The main objective of this study was to determine the cost-utility and budget impact of switching from vaccination with TIV to QIV in the population recommended for influenza vaccination in Turkey.